Sponsor

Fondazione Ricerca Traslazionale

Clinical research sponsor

Published trials13

Recruiting shown3

Roles1

SourceClinicalTrials.gov

Clinical trials

13 shown

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.NCT07392658 · lead sponsor · 2025-12-02

RECRUITING

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)NCT07264647 · lead sponsor · 2025-03-27

RECRUITING

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabNCT05568212 · lead sponsor · 2022-05-02

RECRUITING

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)NCT04884282 · lead sponsor · 2021-10-12

ACTIVE_NOT_RECRUITING

Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsNCT04811001 · lead sponsor · 2020-06-12

UNKNOWN

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)NCT03896074 · lead sponsor · 2020-03-02

ACTIVE_NOT_RECRUITING

Crizotinib in ALK Rearranged Non-small-cell Lung CancerNCT04317651 · lead sponsor · 2019-05-16

UNKNOWN

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET DeregulationNCT03911193 · lead sponsor · 2018-09-21

UNKNOWN

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)NCT03823625 · lead sponsor · 2017-09-13

UNKNOWN

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerNCT03439215 · lead sponsor · 2017-06-13

UNKNOWN

Prognostic Value of PD-L1 in NSCLCNCT03078959 · lead sponsor · 2017-03-03

UNKNOWN

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)NCT03816657 · lead sponsor · 2015-02-15

UNKNOWN

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)NCT02499614 · lead sponsor · 2014-12-01

UNKNOWN

Sponsor roles

lead sponsor13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.